In vitro and in vivo studies of pulmonary hypertension, a mitochondria-related disorder, have demonstrated that treatment with BGP-15 promotes mitochondrial fusion by activating optic atrophy 1 (OPA1). Here, OPA1 is linked to pulmonary hypertension.